Highlights and Quick Summary
Current P/E ratio of AbbVie Inc. is 37.47 (as of December 30, 2020)
- P/E ratio for the quarter ending December 30, 2020 was 37.47 (a 102.32% increase compared to previous quarter)
- Year-over-year quarterly P/E ratio increased by 177.83%
- Annual P/E ratio for 2020 was 37.47 (a 123.42% increase from previous year)
- Annual P/E ratio for 2019 was 16.77 (a -34.88% decrease from previous year)
- Annual P/E ratio for 2018 was 25.75 (a -13.91% decrease from previous year)
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical P/E ratio of AbbVie Inc.
Most recent P/E ratioof ABBV including historical data for past 10 years.Interactive Chart of P/E ratio of AbbVie Inc.
AbbVie Inc. P/E ratio for the past 10 Years (both Annual and Quarterly)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2020 | 37.47 | 18.52 | 20.89 | 13.49 | 37.47 |
2019 | 16.77 | 34.89 | 26.99 | 23.15 | 16.77 |
2018 | 25.75 | 19.63 | 23.05 | 23.04 | 25.75 |
2017 | 29.91 | 21.99 | 17.82 | 16.88 | 29.91 |
2016 | 17.19 | 17.05 | 17.84 | 17.2 | 17.19 |
2015 | 18.99 | 32.2 | 53.33 | 52.74 | 18.99 |
2014 | 60.04 | 25.11 | 21.79 | 20.0 | 60.04 |
2013 | 20.63 | 15.75 | 12.8 | 12.13 | 20.63 |
2012 | 10.48 | 10.48 | 10.48 | 10.48 | 10.48 |
2011 | 10.48 | 10.48 | 10.48 | 10.48 | 10.48 |
2010 | – | – | – | – | 10.48 |
Business Profile of AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.